Vasomotor Symptoms - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Vasomotor Symptoms - Pipeline Insight, 2021,” report provides comprehensive insights about 9+ companies and 9+ pipeline drugs in Vasomotor Symptoms pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Vasomotor Symptoms: Overview
Vasomotor symptoms (VMS), commonly called hot flashes or flushes (HFs) and night sweats, are considered as the cardinal symptoms of menopause. VMS are a form of temperature dysfunction that occurs due to changes in gonadal hormones. Vasomotor symptoms includes hot flashes, night sweats, heart palpitations, and changes in blood pressure. Most women experience hot flashes for 6 months to 2 years, although some women have them for 10 years or longer. Hot flashes occur in approximately 75 to 80 percent of menopausal women in the United States. Hormone therapy, antidepressant drugs and lifestyle modification are ways to manage vasomotor symptoms. Lifestyle modifications, including reducing core body temperature, regular exercise, weight management, smoking cessation, and avoidance of known triggers such as hot drinks and alcohol, may be recommended to reduce mild vasomotor symptoms.
'Vasomotor Symptoms - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vasomotor Symptoms pipeline landscape is provided which includes the disease overview and Vasomotor Symptoms treatment guidelines. The assessment part of the report embraces, in depth Vasomotor Symptoms commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vasomotor Symptoms collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Vasomotor Symptoms report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vasomotor Symptoms Emerging Drugs
Further product details are provided in the report
Vasomotor Symptoms: Therapeutic Assessment
This segment of the report provides insights about the different Vasomotor Symptoms drugs segregated based on following parameters that define the scope of the report, such as:
Vasomotor Symptoms: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vasomotor Symptoms therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vasomotor Symptoms drugs.
Vasomotor Symptoms Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Vasomotor Symptoms - Pipeline Insight, 2021,” report provides comprehensive insights about 9+ companies and 9+ pipeline drugs in Vasomotor Symptoms pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Vasomotor Symptoms: Overview
Vasomotor symptoms (VMS), commonly called hot flashes or flushes (HFs) and night sweats, are considered as the cardinal symptoms of menopause. VMS are a form of temperature dysfunction that occurs due to changes in gonadal hormones. Vasomotor symptoms includes hot flashes, night sweats, heart palpitations, and changes in blood pressure. Most women experience hot flashes for 6 months to 2 years, although some women have them for 10 years or longer. Hot flashes occur in approximately 75 to 80 percent of menopausal women in the United States. Hormone therapy, antidepressant drugs and lifestyle modification are ways to manage vasomotor symptoms. Lifestyle modifications, including reducing core body temperature, regular exercise, weight management, smoking cessation, and avoidance of known triggers such as hot drinks and alcohol, may be recommended to reduce mild vasomotor symptoms.
'Vasomotor Symptoms - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vasomotor Symptoms pipeline landscape is provided which includes the disease overview and Vasomotor Symptoms treatment guidelines. The assessment part of the report embraces, in depth Vasomotor Symptoms commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vasomotor Symptoms collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vasomotor Symptoms R&D. The therapies under development are focused on novel approaches to treat/improve Vasomotor Symptoms.
This segment of the Vasomotor Symptoms report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vasomotor Symptoms Emerging Drugs
- Donesta: Mithra Pharmaceuticals
- Q-122: QUE Oncology
Further product details are provided in the report
Vasomotor Symptoms: Therapeutic Assessment
This segment of the report provides insights about the different Vasomotor Symptoms drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Vasomotor Symptoms
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Vasomotor Symptoms: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vasomotor Symptoms therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vasomotor Symptoms drugs.
Vasomotor Symptoms Report Insights
- Vasomotor Symptoms Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Vasomotor Symptoms drugs?
- How many Vasomotor Symptoms drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vasomotor Symptoms?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vasomotor Symptoms therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vasomotor Symptoms and their status?
- What are the key designations that have been granted to the emerging drugs?
- Mithra Pharmaceuticals
- Acer Therapeutics
- QUE Oncology
- Bayer
- Endoceutics
- Astellas Pharma
- Mitsubishi Tanabe Pharma
- MenoGenix
- Donesta
- Osanetant
- Q-122
- Elinzanetant
- Acolbifene + prasterone
- Fezolinetant
- Elismetrep
- Filgrastim
Introduction
Executive Summary
Vasomotor Symptoms: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vasomotor Symptoms – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vasomotor Symptoms companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vasomotor Symptoms Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Donesta: Mithra Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Q-122: QUE Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Osanetant: Acer Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Vasomotor Symptoms Key Companies
Vasomotor Symptoms Key Products
Vasomotor Symptoms- Unmet Needs
Vasomotor Symptoms- Market Drivers and Barriers
Vasomotor Symptoms- Future Perspectives and Conclusion
Vasomotor Symptoms Analyst Views
Vasomotor Symptoms Key Companies
Appendix
Executive Summary
Vasomotor Symptoms: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vasomotor Symptoms – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vasomotor Symptoms companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vasomotor Symptoms Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Donesta: Mithra Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Q-122: QUE Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Osanetant: Acer Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Vasomotor Symptoms Key Companies
Vasomotor Symptoms Key Products
Vasomotor Symptoms- Unmet Needs
Vasomotor Symptoms- Market Drivers and Barriers
Vasomotor Symptoms- Future Perspectives and Conclusion
Vasomotor Symptoms Analyst Views
Vasomotor Symptoms Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Vasomotor Symptoms
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Vasomotor Symptoms
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Vasomotor Symptoms
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Vasomotor Symptoms
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
